Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis

David Cella, Hilary Wilson, Huda Shalhoub, Dennis A Revicki, Joseph C Cappelleri, Andrew G Bushmakin, Elizabeth Kudlacz, Ming-Ann Hsu, David Cella, Hilary Wilson, Huda Shalhoub, Dennis A Revicki, Joseph C Cappelleri, Andrew G Bushmakin, Elizabeth Kudlacz, Ming-Ann Hsu

Abstract

Background: To evaluate the measurement properties (e.g. content validity, reliability and ability to detect change) of the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale in patients with active psoriatic arthritis (PsA).

Methods: One-on-one semi-structured qualitative interviews with adult patients with active PsA evaluated the content validity of FACIT-Fatigue. Quantitative measurement properties were evaluated using data from phase III tofacitinib randomized controlled trials (RCTs) in PsA: OPAL Broaden (NCT01877668) and OPAL Beyond (NCT01882439).

Results: Of 12 patients included in the qualitative study, 2 (17%) had mild, 8 (67%) had moderate, and 2 (17%) had severe PsA disease activity; 7 (58%) attributed fatigue to PsA, and 7 (58%) rated fatigue as important or extremely important. Most patients considered the FACIT-Fatigue items relevant to their PsA experience and understood item content and response options as intended. In the psychometric analysis of RCT data, a second-order confirmatory factor model fit the data well (Bentler's Comparative Fit Index ≥0.92). FACIT-Fatigue demonstrated good internal consistency (Cronbach's coefficient α ≥ 0.90), test-retest reliability (Intraclass Correlation Coefficient ≥ 0.80) and a strong correlation with SF-36 Vitality (r > 0.80). A robust relationship between disease activity (based on Patient's Global Assessment of Psoriasis and Arthritis) and FACIT-Fatigue was observed (effect sizes > 1.4), with clinically important difference for the FACIT-Fatigue total score estimated as 3.1 points, and the responder definition estimated as a 4-point improvement for FACIT-Fatigue total score.

Conclusion: Fatigue was confirmed to be an important symptom to patients with PsA, and FACIT-Fatigue was found to be a reliable and valid measure in this population.

Keywords: Content validity; FACIT-fatigue; Psoriatic arthritis; Psychometric properties; Tofacitinib.

Conflict of interest statement

David Cella has served on the board of directors for Cancer Wellness Center, and PROMIS Health Organization, has received consultancy fees of <$10,000 from AbbVie, Alexion Pharmaceuticals, Astellas Pharma, Bayer AG, Bristol-Myers Squibb, Celgene Corporation, Clovis Oncology Inc., Evidera, Exelixis Inc., FibroGen Inc., Helsinn Therapeutics (U.S.) Inc., Horizon Pharma Inc., ImmunoGen Inc., Janssen Pharmaceuticals Inc., Merck/Schering-Plough Pharmaceuticals, National Academy of Sciences, Novartis Pharma K.K. (Japan), PatientsLikeMe, Pfizer Inc., Pled Pharma, Puma Biotechnology Inc., Regeneron Pharmaceuticals Inc., and Shire PLC, and has ownership or investment interests in FACITtrans LLC (FACIT.org), and Functional Assessment of Chronic Illness Therapy (FACIT.org). Hilary Wilson, Huda Shalhoub and Dennis A. Revicki are employees of Evidera Inc. Joseph C. Cappelleri, Andrew G. Bushmakin, Elizabeth Kudlacz and Ming-Ann Hsu are employees of Pfizer Inc. and own stock in Pfizer Inc.

Figures

Fig. 1
Fig. 1
Relationship between FACIT-Fatigue total score and PtGA as a continuous or categorical anchor. FACIT-Fatigue: Functional Assessment of Chronic Illness Therapy–Fatigue; PtGA: Patient’s Global Assessment of Psoriasis and Arthritis

References

    1. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome. Annals of the Rheumatic Diseases. 2005;64(Suppl 2):ii14–ii17.
    1. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, et al. Group for Research and Assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis & Rhematology. 2016;68(5):1060–1071.
    1. Gudu T, Etcheto A, de Wit M, Heiberg T, Maccarone M, Balanescu A, et al. Fatigue in psoriatic arthritis - a cross-sectional study of 246 patients from 13 countries. Joint, Bone, Spine. 2016;83(4):439–443. doi: 10.1016/j.jbspin.2015.07.017.
    1. Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Annals of the Rheumatic Diseases. 2017;76(4):673–680. doi: 10.1136/annrheumdis-2016-210242.
    1. Orbai AM, de Wit M, Mease PJ, Callis Duffin K, Elmamoun M, Tillett W, et al. Updating the psoriatic arthritis (PsA) Core domain set: A report from the PsA workshop at OMERACT 2016. The Journal of Rheumatology. 2017;44(10):1522–1528. doi: 10.3899/jrheum.160904.
    1. Gladman D, Fleischmann R, Coteur G, Woltering F, Mease PJ. Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study. Arthritis Care and Research. 2014;66(7):1085–1092. doi: 10.1002/acr.22256.
    1. Strand V, Schett G, Hu C, Stevens RM. Patient-reported health-related quality of life with apremilast for psoriatic arthritis: A phase II, randomized, controlled study. The Journal of Rheumatology. 2013;40(7):1158–1165. doi: 10.3899/jrheum.121200.
    1. Strand V, Mease P, Gossec L, Elkayam O, van den Bosch F, Zuazo J, et al. Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: Results from a randomised phase III trial (FUTURE 1) Annals of the Rheumatic Diseases. 2017;76(1):203–207. doi: 10.1136/annrheumdis-2015-209055.
    1. FDA. Guidance for industry patient-reported outcome measures: Use in medical product development to support labeling claims. 2009. . Accessed 18 Jan 2019.
    1. Revicki, D., Cella, D., Hays, R., Sloan, J., Lenderking, W., Aaronson, N. (2006) Responsiveness and minimal important differences for patient reported outcomes. Health and Quality of Life Outcomes, 4(70).
    1. Revicki DA, Osoba D, Fairclough D, Barofsky I, Berzon R, Leidy NK, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Quality of Life Research. 2000;9(8):887–900. doi: 10.1023/A:1008996223999.
    1. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis. The Journal of Rheumatology. 2005;32(5):811–819.
    1. Pouchot J, Kherani RB, Brant R, Lacaille D, Lehman AJ, Ensworth S, et al. Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritis. Journal of Clinical Epidemiology. 2008;61(7):705–713. doi: 10.1016/j.jclinepi.2007.08.016.
    1. Chandran V, Bhella S, Schentag C, Gladman DD. Functional Assessment of Chronic Illness Therapy-Fatigue scale is valid in patients with psoriatic arthritis. Annals of the Rheumatic Diseases. 2007;66(7):936–939. doi: 10.1136/ard.2006.065763.
    1. Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the functional assessment of Cancer therapy (FACT) measurement system. Journal of Pain and Symptom Management. 1997;13(2):63–74. doi: 10.1016/S0885-3924(96)00274-6.
    1. Cella D, Lai JS, Stone A. Self-reported fatigue: One dimension or more? Lessons from the functional assessment of chronic illness therapy--fatigue (FACIT-F) questionnaire. Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer. 2011;19(9):1441–1450. doi: 10.1007/s00520-010-0971-1..
    1. Rothman M, Burke L, Erickson P, Leidy NK, Patrick DL, Petrie CD. Use of existing patient-reported outcome (PRO) instruments and their modification: The ISPOR good research practices for evaluating and documenting content validity for the use of existing instruments and their modification PRO task force report. Value in Health. 2009;12(8):1075–1083. doi: 10.1111/j.1524-4733.2009.00603.x.
    1. Kaiser, K., Shaunfield, S., Clayman, M. L., Ruderman, E., & Cella, A. (2016). Content validation of the functional assessment of chronic illness therapy (FACIT)-fatigue scale in moderately to highly active rheumatoid arthritis. Rheumatology Current Research, 6(2). 10.4172/2161-1149.1000193
    1. Friese S, Ringmayr T. ATLAS.ti 7 user guide and reference. Berlin: ATLAS.ti Scientific Software Development GmBH; 2013.
    1. Willis G. Analysis of the cognitive interview in questionnaire design. Understanding qualitative research. New York: Oxford University Press; 2015.
    1. Welch LC, Trudeau JJ, Silverstein SM, Sand M, Henderson DC, Rosen RC. Initial development of a patient-reported outcome measure of experience with cognitive impairment associated with schizophrenia. Patient Related Outcome Measures. 2017;8:71–81. doi: 10.2147/PROM.S123266.
    1. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity—Establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: Part 1—Eliciting concepts for a new PRO instrument. Value in Health. 2011;14(8):967–977. doi: 10.1016/j.jval.2011.06.014.
    1. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et al. Content validity—Establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: Part 2—Assessing respondent understanding. Value in Health. 2011;14(8):978–988. doi: 10.1016/j.jval.2011.06.013.
    1. Boeije H. A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Quality and Quantity. 2002;36(4):391–409. doi: 10.1023/A:1020909529486..
    1. Leidy NK, Vernon M. Perspectives on patient-reported outcomes : Content validity and qualitative research in a changing clinical trial environment. Pharmacoeconomics. 2008;26(5):363–370. doi: 10.2165/00019053-200826050-00002.
    1. Mease P, Hall S, Fitzgerald O, van der Heijde D, Merola JF, Avila-Zapata F, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. The New England Journal of Medicine. 2017;377(16):1537–1550. doi: 10.1056/NEJMoa1615975.
    1. Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. The New England Journal of Medicine. 2017;377(16):1525–1536. doi: 10.1056/NEJMoa1615977.
    1. Reeve BB, Wyrwich KW, Wu AW, Velikova G, Terwee CB, Snyder CF, et al. ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Quality of Life Research. 2013;22(8):1889–1905. doi: 10.1007/s11136-012-0344-y.
    1. McDowell I. Measuring health: A guide to rating scales and questionnaires. USA: Oxford University Press; 2006.
    1. Tveter AT, Dagfinrud H, Moseng T, Holm I. Measuring health-related physical fitness in physiotherapy practice: Reliability, validity, and feasibility of clinical field tests and a patient-reported measure. The Journal of Orthopaedic and Sports Physical Therapy. 2014;44(3):206–216. doi: 10.2519/jospt.2014.5042..
    1. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care. 2003;41(5):582–592. doi: 10.1097/01.Mlr.0000062554.74615.4c.
    1. Norman GR, Sloan JA, Wyrwich KW. The truly remarkable universality of half a standard deviation: Confirmation through another look. Expert Review of Pharmacoeconomics & Outcomes Research. 2004;4(5):581–585. doi: 10.1586/14737167.4.5.581.
    1. Overman CL, Kool MB, da Silva JA, Geenen R. The prevalence of severe fatigue in rheumatic diseases: An international study. Clinical Rheumatology. 2016;35(2):409–415. doi: 10.1007/s10067-015-3035-6.
    1. Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: Elaboration and preliminary validation of the psoriatic arthritis impact of disease (PsAID) questionnaire, a 13-country EULAR initiative. Annals of the Rheumatic Diseases. 2014;73(6):1012–1019. doi: 10.1136/annrheumdis-2014-205207.
    1. Palimaru Alina Ionela, Cunningham William E., Dillistone Marcus, Vargas-Bustamante Arturo, Liu Honghu, Hays Ron D. Development and Psychometric Evaluation of a Fatigability Index for Full-Time Wheelchair Users With Spinal Cord Injury. Archives of Physical Medicine and Rehabilitation. 2018;99(9):1827-1839.e6. doi: 10.1016/j.apmr.2018.04.003.
    1. Hays RD, Hadorn D. Responsiveness to change: An aspect of validity, not a separate dimension. Quality of Life Research. 1992;1(1):73–75. doi: 10.1007/BF00435438.
    1. Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, et al. The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes. Journal of Clinical Epidemiology. 2010;63(7):737–745. doi: 10.1016/j.jclinepi.2010.02.006.
    1. Gladman DD, Bombardier C, Thorne C, Haraoui B, Khraishi M, Rahman P, et al. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: The REPArE trial. The Journal of Rheumatology. 2011;38(7):1355–1362. doi: 10.3899/jrheum.100698.
    1. Paul C, van de Kerkhof P, Puig L, Unnebrink K, Goldblum O, Thaci D. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: Subanalysis of the BELIEVE study. European Journal of Dermatology. 2012;22(6):762–769. doi: 10.1684/ejd.2012.1863..
    1. Sloan JA, Cella D, Hays RD. Clinical significance of patient-reported questionnaire data: Another step toward consensus. Journal of Clinical Epidemiology. 2005;58(12):1217–1219. doi: 10.1016/j.jclinepi.2005.07.009.
    1. Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. Journal of Clinical Epidemiology. 2008;61(2):102–109. doi: 10.1016/j.jclinepi.2007.03.012.
    1. Beaton DE, Bombardier C, Katz JN, Wright JG, Wells G, Boers M, et al. Looking for important change/differences in studies of responsiveness. OMERACT MCID working group. Outcome measures in rheumatology. Minimal clinically important difference. The Journal of Rheumatology. 2001;28(2):400–405.
    1. Wells G, Beaton D, Shea B, Boers M, Simon L, Strand V, et al. Minimal clinically important differences: Review of methods. The Journal of Rheumatology. 2001;28(2):406–412.
    1. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of Cancer therapy (FACT) anemia and fatigue scales. Journal of Pain and Symptom Management. 2002;24(6):547–561. doi: 10.1016/S0885-3924(02)00529-8.
    1. Cella D, Lai JS, Jensen SE, Christodoulou C, Junghaenel DU, Reeve BB, et al. PROMIS fatigue item Bank had clinical validity across diverse chronic conditions. Journal of Clinical Epidemiology. 2016;73:128–134. doi: 10.1016/j.jclinepi.2015.08.037.
    1. Bartlett S. J., Gutierrez A. K., Butanis A., Bykerk V. P., Curtis J. R., Ginsberg S., Leong A. L., Lyddiatt A., Nowell W. B., Orbai A. M., Smith K. C., Bingham C. O. Combining online and in-person methods to evaluate the content validity of PROMIS fatigue short forms in rheumatoid arthritis. Quality of Life Research. 2018;27(9):2443–2451. doi: 10.1007/s11136-018-1880-x.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren